Latest news
FDA Accepts daraxonrasib Application for RAS-Mutant Pancreatic Cancer - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 11:00:00 GMTLexeo's heart gene therapy gets FDA status after interim data - Stock TitanStock Titan · Wed, 05 Aug 2026 11:00:00 GMTLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For LX2020 For The Treatment Of PKP2 Arrhythmogenic Cardiomyopathy - marketscreener.commarketscreener.com · Wed, 05 Aug 2026 11:00:00 GMTLexeo wins FDA RMAT status for LX2020 - PharmaTimesPharmaTimes · Mon, 03 Aug 2026 22:32:00 GMTOrbimed Advisors LLC Purchases 1,477,450 Shares of Lexeo Therapeutics, Inc. $LXEO - MarketBeatMarketBeat · Mon, 27 Jul 2026 07:00:00 GMTLexeo Therapeutics, Inc. $LXEO Shares Sold by Octagon Capital Advisors LP - MarketBeatMarketBeat · Mon, 27 Jul 2026 07:00:00 GMT